Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, Apr 13 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) announced today that its partner, Neurocrine Biosciences Inc.
(NASDAQ: NBIX), has initiated a Phase 2 clinical trial targeting adult patients with schizophrenia for the oral selective muscarinic M1/M4 receptor agonist NBI1,117,570. As part of their collaboration agreement, Nxera Pharma will receive a $1 million milestone payment upon initiation of the trial. This amount will be fully recognized as revenue in the first quarter of the fiscal year ending December 2026. The Phase 2 trial, which involves approximately 120 hospitalized patients, aims to evaluate the efficacy, safety, and tolerability of NBI__NUM_6__. The primary endpoint measures changes in Positive and Negative Syndrome Scale (PANSS) total scores from baseline at day 35, while secondary endpoints focus on treatment-emergent adverse events.
Schizophrenia affects approximately ¥24 million people globally and incurs annual economic costs exceeding $150 billion in the United States alone. It remains a significant unmet medical need, impacting patients and their families profoundly. Nxera Pharma's NxWave™ technology was used to develop NBI__NUM_6__, marking the second time a compound from their muscarinic program has advanced to Phase 2 trials. Nxera Pharma’s CEO, Christopher Kargil, commented, “We are delighted to report that NBI__NUM_6__ is advancing to Phase 2, following Direclidine (NBI1,117,568). We believe there is potential for NBI__NUM_6__ to contribute positively to patient care.”.
🟢 Confidence: High AI-translated content.